Omburtamab Gets Priority Review for Neuroblastoma
The FDA has accepted for Priority Review the BLA for omburtamab to treat CNS/leptomeningeal metastasis from neuroblastoma.
Source: empr.com
Page 45 - Accessed May News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Accessed May. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Accessed May Today - Breaking & Trending Today
Seqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic Ready
/PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced that the company's manufacturing...
Source: prnewswire.com
Seqirus' Holly Springs Manufacturing Facility Designated by U.S. Government as Pandemic Ready
/PRNewswire/ -- Seqirus, a global leader in influenza prevention and a business of CSL Limited (ASX: CSL), today announced that the company's manufacturing...
Source: prnewswire.com
New Data Show Patients Treated with First-in-Class TREMFYA® (guselkumab) Achieve Durable Efficacy Across Joint and Axial Symptoms of Active Psoriatic Arthritis Through Two Years
/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with...
Source: prnewswire.com
AbbVie Presents Positive Results from Phase 3 SELECT-AXIS 2 Trials of Upadacitinib (RINVOQ®) in Patients with Axial Spondyloarthritis at EULAR 2022
Results from the SELECT-AXIS 2 non-radiographic axial spondyloarthritis (nr-axSpA) study demonstrated significantly greater improvements in signs and symptoms,...
Source: prnewswire.com